Delphi Consensus Recommendations on Management of Dosing, Adverse Events, and Comorbidities in the Treatment of Idiopathic Pulmonary Fibrosis with Nintedanib
Rahaghi F, Belperio JA, Fitzgerald J, Gulati M, Hallowell R, Highland KB, Huie TJ, Kim HJ, Kolb M, Lasky JA, Southern BD, Swigris JJ, de Andrade JA. Delphi Consensus Recommendations on Management of Dosing, Adverse Events, and Comorbidities in the Treatment of Idiopathic Pulmonary Fibrosis with Nintedanib. Clinical Medicine Insights Circulatory Respiratory And Pulmonary Medicine 2021, 15: 11795484211006050. PMID: 33854398, PMCID: PMC8013629, DOI: 10.1177/11795484211006050.Peer-Reviewed Original ResearchIdiopathic pulmonary fibrosisConsensus recommendationsAdverse eventsPulmonary fibrosisPrescribing informationManagement of comorbiditiesManagement of patientsAdverse event managementClinical trial dataEvidence-based literatureReal-world evidenceCytochrome P450 3A4Delphi consensus recommendationsConcomitant medicationsLiver dysfunctionTolerability issuesConcomitant administrationGastrointestinal effectsDisease progressionNintedanibComorbiditiesAppropriate managementTrial dataPatientsP450 3A4